

# Supplementary information

## *AIFM1* variants associated with auditory neuropathy spectrum disorder cause apoptosis due to impaired apoptosis-inducing factor dimerization

Yue QIU<sup>1</sup>, Hongyang WANG<sup>2</sup>, Huaye PAN<sup>1</sup>, Jing GUAN<sup>2</sup>, Lei YAN<sup>1</sup>, Mingjie FAN<sup>1,3</sup>, Hui ZHOU<sup>1</sup>, Xuanhao ZHOU<sup>1</sup>, Kaiwen WU<sup>2</sup>, Zexiao JIA<sup>1</sup>, Qianqian ZHUANG<sup>1</sup>, Zhaoying LEI<sup>1</sup>, Mengyao LI<sup>1</sup>, Xue DING<sup>1</sup>, Aifu LIN<sup>1</sup>, Yong FU<sup>4</sup>, Dong ZHANG<sup>1</sup>, Qiuju WANG<sup>2</sup>, Qingfeng YAN<sup>1,3,5</sup>

<sup>1</sup>College of Life Sciences, Zhejiang University, Hangzhou 310058, China

<sup>2</sup>Senior Department of Otolaryngology, Head and Neck Surgery, Chinese PLA Institute of Otolaryngology, Chinese PLA General Hospital, Beijing 100853, China

<sup>3</sup>Department of Pediatrics, the First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310003, China

<sup>4</sup>The Children's Hospital of Zhejiang University School of Medicine, Hangzhou 310052, China

<sup>5</sup>Key Laboratory for Cell and Gene Engineering of Zhejiang Province, Hangzhou 310058, China

## Materials and methods

### Cell culture

HEK 293T cells were cultured in a complete culture medium (DMEM with 2 mmol/L L-glutamine, 4.5 g/L D-glucose, and 110 mg/L sodium pyruvate, supplemented with 10% FBS, Gibco) and maintained at 37 °C in a humidified 5% CO<sub>2</sub> atmosphere.  $1.2 \times 10^6$  cells were seeded into a 6 cm dish.

### PCR amplification and plasmid construction

Total RNA was obtained using Trizol reagent (Invitrogen) from  $5 \times 10^6$  cells. cDNA was reverse transcribed from one microgram of total RNA using a Prime Script RT reagent Kit (Takara). The *AIFM1* gene was amplified with the corresponding primers (Table 1). Wide-type and mutant *AIFM1* were cloned into several expression vectors (Table 2). These vector constructs were

referred to as pCDH-*AIFM1*-WT/mut, p3×Flag/HA-*AIFM1*-WT/mut, pET28a-*AIFM1*-WT/mut, and pFlag/His-*AIFM1*-WT/ mut. The corresponding primers are listed (Table 1).

**Table 1 Primers for vector construction**

|                                      |         | Sequence (5'→3')                                |
|--------------------------------------|---------|-------------------------------------------------|
| <i>AIFM1</i> -WT                     | Forward | GGGGTACCGAAGGAGGAGGTCCCGAATAG                   |
|                                      | Reverse | CCTTAAGTGCAGTGGGTTTGCCAATTCC                    |
| <i>AIFM1</i> -778A>G <sup>1</sup>    | Forward | GGGGTACCGAAGGAGGAGGTCCCGAATAG                   |
|                                      | Reverse | GTACCTCCTGCTGCAATCAAGC                          |
| <i>AIFM1</i> -778A>G <sup>2</sup>    | Forward | GCTTGATTGCAGCAGGAGGTAC                          |
|                                      | Reverse | CCTTAAGTGCAGTGGGTTTGCCAATTCC                    |
| <i>AIFM1</i> -1264C>T <sup>1</sup>   | Forward | GGGGTACCGAAGGAGGAGGTCCCGAATAG                   |
|                                      | Reverse | TCTGCATTACCCAGAAGCCAC                           |
| <i>AIFM1</i> -1264C>T <sup>2</sup>   | Forward | GTGGCTTCTGGGTAAATGCAGA                          |
|                                      | Reverse | CCTTAAGTGCAGTGGGTTTGCCAATTCC                    |
| <i>AIFM1</i> -1352G>A <sup>1</sup>   | Forward | GGGGTACCGAAGGAGGAGGTCCCGAATAG                   |
|                                      | Reverse | ATGGTGCTCTACCTGCCTCCTT                          |
| <i>AIFM1</i> -1352G>A <sup>2</sup>   | Forward | AAGGAGGCAGGTAGAGCACCAT                          |
|                                      | Reverse | CCTTAAGTGCAGTGGGTTTGCCAATTCC                    |
| pCDH- <i>AIFM1</i>                   | Forward | TAGAAGATTCTAGAGCTAGCGAATTCATGTTCCGGTGTGGAGGCCTG |
|                                      | Reverse | AGCGATCGCAGATCCTTCGCGGCCGCTGCAGTGGGTTTGCCAATTCC |
| p3×Flag- <i>AIFM1</i>                | Forward | TTAAGCTTGC GGCCGCGAATTCATGTTCCGGTGTGGAGGCCTG    |
|                                      | Reverse | TCCTCTAGAGTCGACTGGTACCGTCTTCATGAATGTTGAATA      |
| p3×HA- <i>AIFM1</i>                  | Forward | ATTGAATTCGGGGATCCATGTTCCGGTGTGGAGGCCTG          |
|                                      | Reverse | GTATGGGTAGTCGACTCTAGAGTCTTCATGAATGTTGAATA       |
| pFlag/His- <i>AIFM1</i> <sup>1</sup> | Forward | GCTAGCGCCACCATGGCGGCCGCA ATGTTCCGGTGTGGAGGCCT   |
|                                      | Reverse | TCACCGGTAAGCTTTGCGATCGC GTCTTCATGAATGTTGAATA    |
| pFlag/His- <i>AIFM1</i> <sup>2</sup> | Forward | GCTAGCGCCACCATGGCGGCCGCA GGGCTGACACCAGAACAGAA   |
|                                      | Reverse | TCACCGGTAAGCTTTGCGATCGC GTCTTCATGAATGTTGAATA    |
| pET28a- <i>AIFM1</i>                 | Forward | AATGGGTCGCGGATCCGAATTC GGGCTGACACCAGAACAGAA     |
|                                      | Reverse | TCGAGTGCGGCCGCAAGCTT GTCTTCATGAATGTTGAATA       |

**Table 2 Expression plasmid for vector construction**

| Plasmid               | Company | Cleavage sites                 |
|-----------------------|---------|--------------------------------|
| pCDH-CMV-MCS-EF1-Puro | Novagen | <i>EcoR</i> I/ <i>Not</i> I    |
| p3xFLAG               | Sigma   | <i>EcoR</i> I/ <i>Kpn</i> I    |
| p3xHA                 | Sigma   | <i>Bam</i> H I/ <i>Xba</i> I   |
| pSpCas9(BB)-2A-Puro   | Addgene | <i>Bbs</i> I                   |
| pFlag/His             | Addgene | <i>Not</i> I/ <i>Sfa</i> I     |
| pET28a                | Addgene | <i>EcoR</i> I/ <i>Hind</i> III |

## Generation of AIF-null, AIF-WT, and AIF-mut cell lines

An AIF-null cell line was generated using the CRISPR/Cas9 system. The gRNA was designed online and was cloned into a pSpCas9(BB)-2A-Puro (PX459) V2.0 vector. The detailed protocols

are referred to in Dr. Zhang's paper (Ran et al., 2013). The primers used for CRISPR/Cas9 are listed in Table 3. Subsequently, AIF-WT and AIF-mut stable transfection cell lines were generated using the lentivirus infection system with pCDH-*AIFM1*-WT/mut, psPAX2, and pMD2G co-transfected into AIF-null cells. These were selected using 4 µg/mL puromycin. At least two monoclonal cell lines of each transfection were singled out for subsequent experiments after gene and protein evaluation.

**Table 3 Primers for CRISPR/Cas 9**

|               |         | Sequence (5'→3')          |
|---------------|---------|---------------------------|
| SgRNA-Cas9    | Forward | CACCGCCTCGGGCTTCGGACGCACA |
|               | Reverse | AAACTGTGCGTCCGAAGCCCGAGGC |
| CRISPR-test   | Forward | GAGTCTGCGTAATGTGCG        |
|               | Reverse | AGCCAGTTGTTCTGGGAT        |
| Off-Target-1  | Forward | CTGGCCTGATGCCTTTCAC TG    |
|               | Reverse | GGTGC GTCATAGGCTTGCTG     |
| Off-Target-2  | Forward | CTGGAACCA CGGGTAGTGA      |
|               | Reverse | TCTGCAAGCCAAGGATGAA       |
| Off-Target-3  | Forward | CGGCTCCGCTCGACTTCCT       |
|               | Reverse | GCATTGCCCCCTTTGTTTCC      |
| Off-Target-4  | Forward | GGTGTCCCTTCTCAGTCCC       |
|               | Reverse | CCAAGACCCTTTACCTTTGC      |
| Off-Target-5  | Forward | GCCTCGAACTGTGACATG        |
|               | Reverse | AGGTGGGAGCTGAAACCC        |
| Off-Target-6  | Forward | CCCATGTAACCGCCACCT        |
|               | Reverse | TCCAGCCTCCTCATAGAGC       |
| Off-Target-7  | Forward | GGCTGAGTGTCATTCTC         |
|               | Reverse | CCATCCAGTGATGCCAGAG       |
| Off-Target-8  | Forward | CCCATTATTAACAAGTCCC       |
|               | Reverse | TGCTAATCATGTAGGCAGT       |
| Off-Target-9  | Forward | AAAGCAATTTCTTTCTCTAA      |
|               | Reverse | CCTGATGCTGCGGGTTGG        |
| Off-Target-10 | Forward | GGCGGAGTAGCCCGTGAA        |
|               | Reverse | GCCGCCTGTGGCAGTATCTT      |

## Western blotting analysis

Proteins obtained from cell lines were denatured and loaded on 12% sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE). The proteins were then electro-transferred to PVDF membrane and blocked with Tris-Buffered Saline and Tween20 (TBST) (150 mmol/L NaCl, 10 mmol/L Tris-HCl, pH 7.5 and 0.1% (v/v) Tween 20) containing 5% (w/v) milk for 1 hour. The membranes were then incubated with corresponding primary and secondary antibodies. The primary antibodies are listed in Table 4. Protein signals were detected using a CLINX chemiscope

and the ECL system (CWBIO) with Peroxidase Affini Pure goat anti-mouse IgG and goat anti-rabbit IgG (BIOKER) used as secondary antibodies.

**Table 4 Antibody used for western blot**

| Antibody      | Company         | Lot         |
|---------------|-----------------|-------------|
| anti-AIF      | santa cruz      | ab32516     |
| anti-GAPDH    | abcam           | ab181602    |
| anti-Caspase3 | CST             | #9662       |
| anti-Caspase7 | CST             | #12827      |
| anti-Caspase9 | CST             | #9502       |
| anti-HA       | Sino Biological | 100028-MM10 |
| anti-Flag     | Protein tech    | 20543-1-AP  |

## Native-PAGE

Cells were lysed on ice for 20 min with non-denaturing lysis buffer (50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L DTT, and 0.5% NP-40) containing protease inhibitor cocktail (Roche). The proteins were mixed with 5×Native loading buffer (Fdbio science) and heated at 70 °C for 5 min. The samples were then loaded on 4-15% Precast-gel Tris-Glycine PAGE (Sangon Biotech) using Tris-Glycine Native PAGE Running Buffer (Sangon Biotech). The following steps were similar to those of western blotting analysis.

## Co-IP analysis

Cells were lysed on ice for 20 min with cold lysis buffer (50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L DTT, and 0.5% NP-40) containing protease inhibitor cocktail (Roche). After quantification, 1.5 mg protein was added into 5 µL Flag beads (Sigma) and incubated at 4 °C for 3 h. After incubation, the beads were washed three times with cold lysis buffer and 100 µL 1×loading was added to the beads for further western blotting.

## Protein expression and purification in *E. coli*

All hAIF<sub>Δ1-102</sub> constructs were cloned into the pET28a vector with a C-terminal 6X His affinity tag. They were then transformed into Rosetta2 (DE3) cells. At OD<sub>600</sub> 0.6~0.8, cultures were induced with IPTG at 16 °C overnight. Cells were resuspended in PBS (pH 7.4) containing 1 mmol/L phenylmethyl sulfonyl fluoride and subsequently sonicated at 4 °C for 10 min. The supernatant was incubated with the Ni-affinity resin (Sangon Biotech) at 4 °C overnight. Then, the supernatant was discarded and the Ni-affinity resin was transferred into an Affinity

Chromatography Column (Sangon Biotech). After washing with 40 mmol/L imidazole, AIF was eluted with 150 mmol/L imidazole. The protein solution was concentrated and purified on a UFC5100BK ultrafiltration column (Merck Millipore). The concentration of the purified protein was verified using Bradford assay. Before NADH reduction titration, the purified proteins were oxidized for 2 hours in pure oxygen to completely oxidize the flavin. Protein preparations used in the study had A280/452 ratios  $\leq 7.0$ .

### **Protein expression and purification in eukaryotic cells**

The plasmids of p Flag/His-AIFM1-WT/mute were transfected into AIF-null cells. The cell pellets were collected 48 h after transfection. After extraction, 30 mg protein was mixed with 60  $\mu$ L Flag beads (Sigma) and incubated at 4 °C for 6 h. After incubation, the beads were washed three times with wash buffer (50 mmol/L Tris-HCl (pH 7.4), 500 mmol/L NaCl, 5 mmol/L EDTA, 1 mmol/L DTT, and 1% NP-40). Then, 60  $\mu$ L 3 $\times$ Flag Peptide (Sigma) was added to the beads for competitive elution of the recombinant protein overnight. In eukaryotic cells, the N-terminal of AIF precursor will be cleaved to form AIF $_{\Delta 1-54}$  proteins. The concentration of the purified protein was verified using Bradford assay. Before NADH reduction titration, the purified proteins were oxidized for 2 h in pure oxygen to fully oxidize the flavin.

### **Kinetics of AIF reduction with NADH**

After purification in *E. coli*, 10  $\mu$ mol/L AIF was dissolved in PBS (pH 7.4). Absorbance spectra were measured on a Spark 10M spectrophotometer (TECAN). The basal value was measured firstly without NADH. Then, 100  $\mu$ mol/L NADH was added to prime FAD reduction and CTC formation. Absorbances from 400 to 800 nm were again detected at 20, 40, 60, 120, 240 and 480 s after mixing AIF protein with NADH at room temperature.

### **Western blotting analysis of AIF reduction with NADH**

After purification in eukaryotic cells and in *E. coli*, 1  $\mu$ mol/L AIF was mixed with various concentrations of NADH (5, 10, and 20  $\mu$ mol/L) and the reaction was incubated for 15 min at room temperature to reduce AIF. Then, 1 mmol/L disuccinimidyl suberate (DSS) was added to crosslink the AIF dimer via incubating for 30 min at room temperature. Reactions were quenched using 1 $\times$ SDS loading buffer, followed by boiled and subjected to SDS-PAGE.

## **Western blotting analysis of AIF dimer in stably transfected cell lines**

The stably transfected cell lines of wild type AIF and AIF variants were seeded 24 h before NADH treatment. Then, 200  $\mu\text{mol/L}$  NADH was added and incubated for 24 h. After treatment,  $1 \times 10^6$  cells were incubated with 4 mmol/L DSS to crosslink the AIF dimer. Reactions were quenched using 20 mmol/L Tris (pH 8.0) for 15 min at room temperature. The proteins were then extracted and subjected to SDS-PAGE.

## **Apoptosis analysis**

The apoptosis of cells was detected using an Annexin V-FITC/PI Apoptosis Detection Kit (YEASEN) through flow cytometry according to the manufacturer's instructions. Blank control: cells were incubated without staurosporine (STS) and Z-VAD-FMK to measure background cell apoptosis. Apoptosis stimulation: cells were incubated only with 1  $\mu\text{mol/L}$  STS (Gene Operation) for 1.5 h. Selectively induced caspase-independent apoptosis: cells were incubated with 1  $\mu\text{mol/L}$  STS for 1.5 h and pre-incubated with 50  $\mu\text{mol/L}$  Z-VAD-FMK (MCE) for 0.5 h.

## **Models of free AIF and AIF-Ligands starting structure**

The starting structures of AIF monomers were generated using the SWISS-MODEL server, according to chain A and chain C of the reduced AIF complexed with NAD (PDB: 4BUR) (Ferreira et al., 2014; Waterhouse et al., 2018). The AIF dimer structure was then created corresponding to the coordinates of AIF-4BUR. This model was subsequently used to generate the AIF-1FAD-2NADH dimer. To simulate the reducing physiological environment, the  $\text{NAD}^+$  was modeled to its reduced form (NADH) by adding an electron to N1 and a hydrogen atom to C4 in the pyridine ring. Coordinates for the FAD and NADH (A and B) ligands from the reduced AIF complexed with NAD (PDB: 4BUR) were placed into the active site. All AIF variants (p.T260A, p.R422W, p.R451Q) were generated using PyMOL.

## **Molecular dynamics simulation**

To test the stability of the AIF dimer in AIF variants, an all-atom molecular dynamics simulation was performed. The simulations were carried out using the GROMACS software package (version 2020.6) (Hess et al., 2008), together with the CHARMM36 force field set in an explicit TIP3P water solvent. The temperature is 300 K and the pressure is 1 bar. The long-range electrostatic interactions were analyzed via PME method and the van der Waals (vdW) interactions were calculated using a cutoff distance of 1.0 nm. The forcefield in the form of charmm-36 for FAD and NADH was generated from the Ligand Reader & Modeler in the CHARMM-GUI server (Brooks

et al., 2009; Lee et al., 2016; Kim et al., 2017). The AIF dimers with or without ligands were solvated in a 12.5 Å x 12.5 Å x 12.5 Å water box with a 60310 TIP3P water model. The system was then neutralized with 187 sodium and 185 chloride ions in a normal saline concentration. The solvated system was firstly energy-minimized by 10,000 steps, followed by a 2500, 000 step equilibration (2 fs for each step). For each system, 300 ns long simulations were performed in 3 replicates. The backbone atoms of residues from 128 to 611 were used to evaluate the RMSDs. The number of H-bonds between residues at the dimer interface along the trajectory were analyzed.

## Statistical analysis

Statistical analysis was carried out using Student's unpaired, two-tailed *t*-tests in the Microsoft-Excel program. All data represent two control AIF-WT cell lines (2 clones) and two AIF-variants cell lines (2 clones) with at least three independent experiments performed. Three replicates for each clone were performed in three independent experiments. Data are represented as mean±SEM. <sup>ns</sup>*P*≥0.05, \**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.001.

## References

- Brooks BR, Brooks CL, 3rd, Mackerell AD, Jr., et al., 2009. Charmm: The biomolecular simulation program. *J Comput Chem*, 30(10):1545-1614. <https://doi.org/10.1002/jcc.21287>
- Ferreira P, Villanueva R, Martínez-Júlvez M, et al., 2014. Structural insights into the coenzyme mediated monomer-dimer transition of the pro-apoptotic apoptosis inducing factor. *Biochemistry*, 53(25):4204-4215. <https://doi.org/10.1021/bi500343r>
- Hess B, Kutzner C, Van Der Spoel D, et al., 2008. Gromacs 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. *J Chem Theory Comput*, 4(3):435-447. <https://doi.org/10.1021/ct700301q>
- Kim S, Lee J, Jo S, et al., 2017. Charmm-gui ligand reader and modeler for charmm force field generation of small molecules. *J Comput Chem*, 38(21):1879-1886. <https://doi.org/10.1002/jcc.24829>
- Lee J, Cheng X, Swails JM, et al., 2016. Charmm-gui input generator for namd, gromacs, amber, openmm, and charmm/openmm simulations using the charmm36 additive force field. *J Chem Theory Comput*, 12(1):405-413. <https://doi.org/10.1021/acs.jctc.5b00935>
- Ran FA, Hsu PD, Wright J, et al., 2013. Genome engineering using the crispr-cas9 system. *Nat Protoc*, 8(11):2281-2308. <https://doi.org/10.1038/nprot.2013.143>
- Waterhouse A, Bertoni M, Bienert S, et al., 2018. Swiss-model: Homology modelling of protein structures and complexes. *Nucleic Acids Res*, 46(W1):W296-w303. <https://doi.org/10.1093/nar/gky427>

Supplemental figures






Fig. S1 Identification of *AIFM1* sequence in the AIF-WT and AIF variants cell lines. The *AIFM1* variants (c.778A>G (a), c.1264C>T (b), and c.1352G>A (c)) were present in the AIF variants cell lines, but absent in the AIF-WT cell lines.





**Fig. S2 FAD reduction assays of AIF<sub>Δ1-102</sub> proteins in eukaryotic cells and *E. coli*. Western blotting analysis after mixing 1 μmol/L AIF<sub>Δ1-102</sub> proteins in eukaryotic cells (a) and in *E. coli* (b) with various concentrations of NADH (5, 10, and 20 μmol/L) for 15-min incubation. DSS was added to crosslink the AIF dimer.**



**Fig. S3 Unstable AIF dimer structure.** (a) Smoothed RMSD values (0.5 ns window) plotted across the trajectory time course without ligand. MD simulations were performed for 300 ns. (b) Smoothed RMSD values (0.5 ns window) were plotted across the trajectory time course with NADH and FAD ligands. MD simulations were performed for 300 ns. (c) Structure of redox active site in AIF-WT, (d) p.T260A, (e) p.R422W, (f) p.R451Q. These selected snapshots were the most stable structures from the trajectories. These conformations were then analyzed, and figures produced using PyMOL. The residues were colored by element, with the C atom in green, the H atom in silver, the N atom in blue, the O atom in red, and the S atom in yellow. The NADH(A/B) is shown in pink and the FAD in yellow. Dashed red lines represent hydrogen bonds.